Physician profile
Brent Cham
NPI 1265061600
$2,958.45
in general payments reported to CMS, 2019-2025
26 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $607 · 2024: $1,182 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.53 |
| Education | $330.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $477.88 | 2024-2025 | Yescarta |
| Genzyme Corporation | $352.12 | 2023-2024 | |
| Astellas Pharma US INC | $207.57 | 2023-2024 | Xospata |
| Incyte Corporation | $188.68 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Celgene Corporation | $165.75 | 2023-2025 | Reblozyl, Opdivo |
| Pfizer INC. | $148.26 | 2024 | |
| Seagen INC. | $137.27 | 2023 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $136.11 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $133.45 | 2023-2025 | Enhertu, Tagrisso, Imfinzi |
| Eisai INC. | $115.92 | 2024-2025 | |
| Janssen Biotech, INC. | $108.85 | 2025 | Rybrevant, Carvykti, Talvey |
| Genentech USA, INC. | $103.41 | 2023-2025 | Tecentriq, Columvi |
| Merck Sharp & Dohme LLC | $84.10 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $82.17 | 2024-2025 | |
| Daiichi Sankyo INC. | $81.47 | 2024-2025 | Enhertu, Datroway |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $72.39 | 2023-2024 | |
| Lilly USA, LLC | $65.12 | 2025 | Verzenio, Jaypirca, Retevmo |
| Adc Therapeutics America, INC. | $51.89 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $43.13 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $41.69 | 2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $34.15 | 2024 | Xpovio |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Dendreon Pharmaceuticals LLC | $29.91 | 2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $23.59 | 2025 | |
| Syndax Pharmaceuticals, INC. | $22.58 | 2025 | |
| Gilead Sciences, INC. | $20.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Cham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.